INTRATHECAL INJECTION OF HYDROMORPHONE FOR POST-CESAREAN ANALGESIA

QIFEI LI¹, FAN YANG², KUN ZHANG³, WEI WANG¹, SHANSHAN CAI⁴, RUI XIA¹

¹Department of Anesthesiology, The First People’s Hospital of Jinzhou, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, 434000, P. R. China - ²Department of Anesthesiology, First people’s Hospital of Yidu, Yidu, Hubei, 434000, P. R. China - ³Department of Anesthesiology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, Hubei, 434000, P. R. China - ⁴Department of Cardiovascular, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei 430000, China

This study aimed to investigate clinical analgesia efficacy of intrathecal hydromorphone for women with cesarean section. 1,500 women with cesarean section and spinal anesthesia were chosen from May 2013 to October 2014 in four hospitals and randomly divided into two groups including control group (750 patients) with intrathecal sufentanil and observation group (750 patients) with intrathecal hydromorphone; and the pain scores at 4 h, 12 h and 24 h after cesarean, painless time and adverse events in both groups were compa- red. The pain scores at 12 h and 24 h after cesarean were significantly better in observation group than in control groups (P<0.05). The painless time was significantly longer in observation group than in control groups (P<0.05). There was no significant difference in adverse events between two groups (P>0.05). In conclusion, compared with intrathecal sufentanil intrathecal hydromorphone provides better analgesia efficacy for cesarean section and does not increase the risk of adverse events.